

Date: 03/04/2017

FREEDOM OF INFORMATION REQUEST FOI/013333 – Melanoma

Within your health trust how many patients are currently [within the past 6 months] being treated for Melanoma ?  
63

Of these Melanoma patients how many are being treated for stage IV (advanced or metastatic) melanoma ?  
19

Of these how many are being treated for (advanced or metastatic) melanoma with the following;  
The Trust's Pharmacy system does not give indications for the drugs, the information would be held in patient notes which are exempt from the Act.

| <u>Drug Name</u>                      | <u>Number of Patients</u> |
|---------------------------------------|---------------------------|
| Ipilimumab (Yervoy) single agent      |                           |
| Ipilimumab (Yervoy) in combination    |                           |
| Nivolumab (Opdivo)                    |                           |
| Pembrolizumab (Keytruda)              |                           |
| vemurafenib (Zelboraf) single agent   |                           |
| vemurafenib (Zelboraf) in combination |                           |
| dabrafenib (Tafinlar)                 |                           |
| trametinib (Mekinist)                 |                           |
| dabrafenib AND trametinib             |                           |
| dacarbazine (DTIC)                    |                           |

How many patients are currently [within the past 6 months] being treated for **Non Squamous** Cell Lung Cancer with the following;  
The Trust's Pharmacy system does not give indications for the drugs, the information would be held in patient notes which are exempt from the Act.

| <u>Drug Name</u>         | <u>Number of Patients</u> |
|--------------------------|---------------------------|
| Afatinib (Giotrif)       |                           |
| Ceritinib (Zykadia)      |                           |
| Crizotinib (Xalkori)     |                           |
| Erlotinib (Tarceva)      |                           |
| Gefitinib (Iressa)       |                           |
| Pemetrexed (Alimta)      |                           |
| Nivolumab (Opdivo)       |                           |
| Pembrolizumab (Keytruda) |                           |

How many patients are currently [within the past 6 months] being treated for Renal Cell Carcinoma (RCC) with the following;

The Trust's Pharmacy system does not give indications for the drugs, the information would be held in patient notes which are exempt from the Act.

| <u>Drug Name</u>                               | <u>Number of Patients</u> |
|--|---------------------------|
| Interferon (Intron A)                          |                           |
| Bevacizumab (Avastin)                          |                           |
| Sunitinib (Sutent)                             |                           |
| Pazopanib (Votrient)                           |                           |
| Aldesleukin (IL-2, Proleukin or interleukin 2) |                           |
| Sorafenib (Nexavar)                            |                           |
| Everolimus (Afinitor)                          |                           |
| Temsirolimus (Torisel)                         |                           |
| Cabozantinib (Cometriq)                        |                           |